Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of EVA-001 versus hyaluronic acid for knee osteoarthritis
jRCT2033210646Phase 3Active, not recruiting
- Sponsor
- MEDIPOST
- Start
- Apr 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of EVA-001 in knee osteoarthritis (OA) (2 arms), sponsored by MEDIPOST. Primary endpoints: Change from baseline in WOMAC scale at 52 weeks post-treatment and Percentage of participants with improvement in ICRS grade by 1 grade or more at 52 weeks post-treatment. Started Apr 2022; status: active, not recruiting.
02
Drugs
EVA-001
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2033210646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210646.